Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients

Lancet Oncology Recently published reports updating the findings from the phase 3 DREAMM 7 trial involving 494 patients averaging ages 64.5 years with the median follow-up of 39.4 months. Accordingly, patients…

Continue Reading Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients

Calidi Biotherapeutics’ CLD-201 Secures FDA Fast Track for Innovative Glioblastoma Therapy

Calidi Biotherapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation to its experimental therapy, CLD-201 SuperNova, for the treatment of glioblastoma.…

Continue Reading Calidi Biotherapeutics’ CLD-201 Secures FDA Fast Track for Innovative Glioblastoma Therapy

A Mother’s Thoughts When Her Two-Year-Old Daughter Was Diagnosed with Acute Lymphoblastic Leukemia

Imagine the highs and lows that accompany the doctor’s announcement that your sweet, innocent two-year-old daughter has leukemia. The good news is that your daughter has the type of leukemia…

Continue Reading A Mother’s Thoughts When Her Two-Year-Old Daughter Was Diagnosed with Acute Lymphoblastic Leukemia
Experimental New Drug Offers Hope for Rare Salivary Gland Cancer
Source: Pixabay

Experimental New Drug Offers Hope for Rare Salivary Gland Cancer

Another great breakthrough in research science! A new study found that an experimental drug combined with the traditional chemotherapy drug cisplatin successfully eliminated a rare salivary gland tumor and prevented a recurrence…

Continue Reading Experimental New Drug Offers Hope for Rare Salivary Gland Cancer